VIVEbiotech, a Spanish lentiviral vector (LVV) CDMO, has added EvoLVcell to its catalog of LVV-manufacturing products. EvoLVcell is a stable producer cell line (SCL) generation platform designed to reduce batch‑to‑batch variability, improve vector quality, and provide a more predictable long‑term production strategy for LVVs. The fully integrated platform requires only the addition of a developer’s transgenic element to the fully characterized monoclonal PCL, avoiding transfection, explained a VIVEbiotech spokesperson, who added that this simplifies the manufacturing workflow, improving long-term predictability and reducing reliance on plasmid and transfection reagent supply chains.
The characterized, inducible, monoclonal lentiviral packaging cell line (PCL) derisks SCL generation by incorporating the therapeutic transgene that typically would be transfected together with the helper plasmids, noted Andrés Lamsfus-Calle, PhD, product development manager at VIVEbiotech. This SCL platform generation enables VIVEbiotech to get a prototype cell line in three months, pointed out Lamsfus-Calle.
EvoLVcell reduces variability and produces fewer impurities, of particular importance to gene therapeutics, according to a company statement. “At the same time, the platform’s extensive characterization enables rapid yield assessment through a rapid proof-of-concept, allowing developers to reach a clear go/no-go inflection point in just three months,” continued the statement.
“Achieving cost efficiency and high reproducibility is essential for the scalable production of lentiviral vectors and for expanding patient access. Stable producer cell lines provide a reliable and scalable manufacturing platform to support this goal,” said Lamsfus-Calle.